What's New

Health Canada Approves Orkambi

As many of you may be aware, Health Canada granted approval to the new drug, Orkambi, in late January this year. In anticipation of the interest this is likely to generate among CF patients and their friends and family members, we have prepared a brief FAQ about Orkambi which you can access here. If you have any questions about this medication that are not addressed in the FAQ, please contact the clinic.

Aztreonam Lysine in CF (AZLI)

The purpose of this study is to observe the effects of aztreonam lysine for inhalation (AZLI, trade name Cayston) on Pseudomonas aeruginosa levels in sputum. We are enrolling patients who take Cayston as part of their usual medication regimen. Sputum is to be collected every two weeks during both the ON and OFF cycles of Cayston, over a span of 58 days. Enrollment is open for this study.

For more information, please contact Eri Flores at (604) 682-2344 ext. 63721 or eflores@providencehealth.bc.ca.

We want to hear from you. Complete our patient satisfaction survey.

Posted with permission.  ©Peter Battistoni/Vancouver Sun

The Adult Cystic Fibrosis Clinic at St. Paul's Hospital wants to hear from patients.

We're launching a new website!

The Adult Cystic Fibrosis Clinic at St. Paul's Hospital is launching its new website!